Epigenomic?s AG Announces 2013 Third Quarter and 9-Month Financial Results and Reports on Operationa?l Highlights

 Epigenomics AG, the German–American cancer molecular diagnostics company, has announced its financial results for the third quarter and the 9 months ending 30 September 2013. 

 
• 9M 2013 revenue increased by 43% to EUR 961 thousand

• 9M 2013 operating costs decreased by 40% to EUR 6.6 million

• 9M 2013 EBIT improved by 45% to EUR -5.2 million 

• Strategic partnerships with Polymedco for the US and BioChain for China (after period-end)

• Successful financing of EUR 5.2 million closed (thereof EUR 4.7 million after period-end)

• Supervisory Board re-appoints Thomas Taapken as CEO/CFO until end of 2015.

“In the past weeks we have achieved significant progress as evidenced by two strategically important collaborations we entered into with Polymedco and BioChain and by securing a EUR 5.2 million financing for the future development of our company. We are especially proud that both of our new partners, BioChain and Polymedco, have expressed their commitment and trust in Epigenomics by becoming strategic investors,, said Thomas Taapken, CEO/CFO of Epigenomics AG.

“Investor confidence in Epigenomics finally seems to be returning; our share price has tripled since the beginning of this year. We are committed to live up to these high expectations to the benefit of our shareholders and partners and remain confident to receive FDA approval for Epi proColon in the near future.”  

Click here for the full 2013 Third Quarter and 9-Month Financial Report